ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
February 03 2020 - 7:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of direct lytic
agents (DLAs), including lysins and amurin peptides, as new medical
modalities for the treatment of life-threatening,
antibiotic-resistant infections, today announced that Jane E.
Ambler, Ph.D. has been appointed as Vice President of Clinical
Microbiology. Dr. Ambler will lead the the Company’s microbiology
efforts in support of the pivotal Phase 3 DISRUPT (Direct Lysis of
Staph aureus Resistant Pathogen Trial) superiority study of
exebacase in patients with Staphylococcus aureus bacteremia,
including right-sided endocarditis and in advancement of the
Company’s pipeline of DLAs. Dr. Ambler has over 25 years of
experience in clinical laboratory microbiology and antimicrobial
drug development, and she has numerous book and journal
publications.
“I’m thrilled that Jane is joining the
ContraFect team. As a recognized leader in clinical microbiology,
she brings a depth of knowledge, wealth of experience and the
energy and enthusiasm to move our novel DLA programs forward,” said
Cara Cassino, M.D., Chief Medical Officer and Executive Vice
President of Research. “Jane is a tremendous addition to our team
and will play an integral role in our mission to address the unmet
need of improving clinical outcomes for serious bacterial
infections and to combat antimicrobial resistance with novel
therapeutics.”
“I am excited to join the team at ContraFect.
The need for novel therapeutic regimens to overcome the challenge
of antimicrobial resistance has never been greater. Traditional
antibiotics alone are no longer sufficient and a new approach is
sorely needed. ContraFect is poised to disrupt the antimicrobial
arena with its novel therapeutic modalities, and I look forward to
helping the company advance them,” said Dr. Ambler, Vice President
of Clinical Microbiology.
Prior to joining ContraFect, Dr. Ambler served
as Vice President of Clinical Microbiology at Wockhardt
Pharmaceuticals Inc., where she was responsible for clinical
microbiology across multiple antimicrobial programs, including
nafithromycin, cefepime-zidebactam, cefepime/tazobactam and Emrok
(levonadifloxacin), which was recently approved in India. Prior to
this, Dr. Ambler was the Senior Director of Clinical Microbiology
at Cubist Pharmaceuticals, Inc., where she led the clinical
microbiology team with responsibility for legacy antibiotics
Cubicin and Dificid, and the European approvals of Sivextro and
Zerbaxa. Prior to Cubist Pharmaceuticals, Inc., Dr. Ambler served
in various roles of increasing responsibility at AstraZeneca (US),
Bayer (US, Germany and UK) and Smithkline Beecham (UK). She
received her Ph.D. from The School of Pharmacy at the University of
London, United Kingdom.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of DLAs, which
include lysins and amurin peptides. Lysins are a new class of DLAs
which are recombinantly produced antimicrobial proteins with a
novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics. Amurin peptides are a new class of DLAs,
which exhibit broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, including Pseudomonas
aeruginosa, Acinetobacter baumannii, and Enterobacter species. We
believe that the properties of our lysins and amurin peptides will
make them suitable for targeting antibiotic-resistant organisms,
such as methicillin-resistant Staphylococcus aureus (MRSA) and P.
aeruginosa, which can cause serious infections such as bacteremia,
pneumonia and osteomyelitis. We have completed a Phase 2 clinical
trial for the treatment of Staph aureus bacteremia, including
endocarditis, with our lead lysin candidate, exebacase, which is
the first lysin to enter clinical studies in the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
Forward-Looking Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding ContraFect’s
ability to discover and develop DLAs as new medical modalities for
the treatment of life-threatening, antibiotic-resistant infections,
statements made regarding Dr. Ambler, including but not limited to,
her intended role and past experience, statements made by Dr.
Cassino and Dr. Ambler, ContraFect’s ability to address life
threatening infections using its DLA platform, whether lysins are a
new class of DLAs which are recombinantly produced, antimicrobial
proteins with a novel mechanism of action associated with the rapid
killing of target bacteria, eradication of biofilms and synergy
with conventional antibiotics, whether amurins exhibit
broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens and whether the
properties of ContraFect’s lysins and amurins will make them
suitable for targeting antibiotic-resistant organisms, such as
Staph aureus and P. aeruginosa. Forward-looking statements are
statements that are not historical facts, nor assurances of future
performance. Instead, they are based on ContraFect’s current
beliefs, expectations and assumptions regarding the future of its
business, future plans, strategies, projections, anticipated events
and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including those detailed under the caption “Risk Factors”
in ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024